*EHVA statement on COVID-19*

EHVA shares the deep concern about the global health crisis that the COVID-19 pandemic presents, and feels a tremendous responsibility to address the urgent health needs of people affected by pandemics, both existing and new.

Like the work of so many in the HIV/AIDS and broader research community, work in our consortium has been much impacted by COVID-19. A large number of our collaborators are working and collaborating from their homes, advancing our research virtually where that is feasible. Many of clinical partner teams are working at the frontline of this new pandemic, caring for patients across Europe. EHVA researchers are utilizing their expertise to help expand access to testing, whilst working on new diagnostics, drugs and vaccines. Importantly, our community partner EATG is monitoring access to care and treatment for people living with HIV, supporting their needs to stay healthy, and providing up to date evidence related to COVID and HIV. We do all this whilst adhering to social distancing and keeping our community safe and healthy.

The work of EHVA, including our HIV vaccine discovery and development work, and ability to initiate new trials, are expected to be delayed as a result of the COVID-19 pandemic, and we are in regular contact with our collaborators and funders to assess the impact as the pandemic continues to evolve. We remain committed to our goal to developing safe, effective vaccines for HIV prevention and treatment, and will continue this important mission as best as possible, whilst working in parallel to addressing the pressing needs in the COVID response.

For anyone with questions about how EHVA is impacted by and responding to COVID-19, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.


This project has received funding from the European Union's Horizon 2020 research
and innovation programme under grant agreement N° 681032